410 related articles for article (PubMed ID: 25350950)
1. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Williams KH; Vieira De Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Brooks B; Bu Y; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Keane FM; Zekry A; Gorrell MD; Twigg SM
J Diabetes; 2015 Nov; 7(6):809-19. PubMed ID: 25350950
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
3. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Williams KH; Viera de Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Bu Y; Brooks B; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Bachovchin WW; Keane FM; Zekry A; Twigg SM; Gorrell MD
Diabetes Res Clin Pract; 2015 Jun; 108(3):466-72. PubMed ID: 25836944
[TBL] [Abstract][Full Text] [Related]
4. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.
Williams KH; Burns K; Constantino M; Shackel NA; Prakoso E; Wong J; Wu T; George J; McCaughan GW; Twigg SM
J Diabetes Complications; 2015; 29(8):1240-7. PubMed ID: 26297218
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population.
Zheng T; Chen B; Yang L; Hu X; Zhang X; Liu H; Qin L
Metabolism; 2017 Aug; 73():125-134. PubMed ID: 28637594
[TBL] [Abstract][Full Text] [Related]
6. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
7. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
8. Lysyl Oxidase as a Serum Biomarker of Liver Fibrosis in Patients with Severe Obesity and Obstructive Sleep Apnea.
Mesarwi OA; Shin MK; Drager LF; Bevans-Fonti S; Jun JC; Putcha N; Torbenson MS; Pedrosa RP; Lorenzi-Filho G; Steele KE; Schweitzer MA; Magnuson TH; Lidor AO; Schwartz AR; Polotsky VY
Sleep; 2015 Oct; 38(10):1583-91. PubMed ID: 26085300
[TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
10. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.
Barchetta I; Ceccarelli V; Cimini FA; Barone E; Sentinelli F; Coluzzi M; Chiappetta C; Bertoccini L; Tramutola A; Labbadia G; Di Cristofano C; Silecchia G; Leonetti F; Cavallo MG
J Endocrinol Invest; 2021 May; 44(5):979-988. PubMed ID: 32852705
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
[TBL] [Abstract][Full Text] [Related]
14. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
15. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
[TBL] [Abstract][Full Text] [Related]
16. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Castera L
Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
[TBL] [Abstract][Full Text] [Related]
18. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
20. Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease.
Kamarajah SK; Chan WK; Nik Mustapha NR; Mahadeva S
Hepatol Int; 2018 Jan; 12(1):44-55. PubMed ID: 29372507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
